Schmidt, Timothy M. http://orcid.org/0000-0002-5860-2640
Barwick, Benjamin G. http://orcid.org/0000-0001-9810-3566
Joseph, Nisha
Heffner, Leonard T.
Hofmeister, Craig C. http://orcid.org/0000-0003-4816-1607
Bernal, Leon
Dhodapkar, Madhav V.
Gupta, Vikas A.
Jaye, David L.
Wu, Jiayi
Goyal, Subir
Chen, Zhengjia
Boise, Lawrence H.
Lonial, Sagar
Nooka, Ajay K.
Kaufman, Jonathan L. http://orcid.org/0000-0002-5687-6429
Funding for this research was provided by:
Genentech
Amgen
Article History
Received: 3 May 2019
Revised: 16 September 2019
Accepted: 19 September 2019
First Online: 25 November 2019
Conflict of interest
: L.T.H. declares research funding from Pharmacyclics, Genentech, Kite Pharma, and ADC Therapeutics. C.C.H. declares research funding from Bristol-Myers Squibb and membership on an advisory committee for Celgene, Oncopeptides, Adaptive Biotechnologies, and Janssen. M.V.D. declares membership in advisory boards for Amgen, Janssen, Roche, Celgene, Kite, and Lava Therapeutics. L.H.B. declares consultancy for Abbvie and Genentech, and honoraria and research funding from AstraZeneca. S.L. declares research funding from Amgen. A.K.N. declares consultancy and/or membership on an advisory committee for Spectrum Pharmaceuticals, Bristol-Myers Squibb, Adaptive Biotechnologies, Amgen, Celgene, Takeda, GlaxoSmithKline, and Janssen. J.L.K. declares consultancy for Celgene, Takeda, Amgen Janssen, and Sanofi. The remaining authors declare that they have no conflict of interest.